Experimental and Molecular Pathology
About: Experimental and Molecular Pathology is an academic journal published by Elsevier BV. The journal publishes majorly in the area(s): Cancer & Population. It has an ISSN identifier of 0014-4800. Over the lifetime, 4459 publications have been published receiving 106992 citations.
Papers published on a yearly basis
TL;DR: This article presents an overview of nanotechnology for the biologist and discusses the attributes of the novel XPclad((c)) nanoparticle formulation that has shown efficacy in treating solid tumors, single dose vaccination, and oral delivery of therapeutic proteins.
TL;DR: The serendipitous discovery of the G-rich oligonucleotides led to the identification of nucleolin as a new molecular target for cancer therapy, and this molecule functions as an aptamer to nucleolin, a multifunctional protein that is highly expressed by cancer cells, both intracellularly and on the cell surface.
TL;DR: Evidence supports the interpretation that Type 2 cells may transform into Type 1 cells when exposed to NO 2 and under the conditions of this experiment: the time for transformation was about 2 days, and during this process an intermediate cell type was present.
TL;DR: Physicians seeking systematic treatments for their patients might consider testing urinary organic acids to determine how best to treat mitochondrial diseases and dysfunction, and antioxidant therapies hold promise for improving mitochondrial performance.
TL;DR: The mechanisms by which virulence factors promote UPEC survival and growth within the urinary tract are discussed and Comparisons are made between UPEC and other strains of extraintestinal pathogenic E. coli that are distinct in their abilities to colonize the host and cause disease.